Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767689 | 0.89 | KMT2A (0.51) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL28022629 | 0.87 | POLB (0.56) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL777815 | 0.85 | KMT2A (0.58) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL15582422 | 0.85 | KMT2A (0.54) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL15582450 | 0.84 | KMT2A (0.50) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL28820872 | 0.83 | KMT2A (0.53) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL777822 | 0.83 | CA1 (0.55) | KMT2AESR1MEN1NPC1RAB9A | |
| SCHEMBL767954 | 0.83 | KMT2A (0.46) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL777641 | 0.81 | KMT2A (0.59) | KMT2AESR1MEN1CASP3SENP8 | |
| SCHEMBL10039543 | 0.81 | KMT2A (0.62) | KMT2AESR1MEN1CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404794-B2 | Liquid crystal compositions | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404794-B2 | Liquid crystal compositions | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8344175-B2 | Liquid crystal compositions, polymer networks derived therefrom and process for making the same | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344175-B2 | Liquid crystal compositions, polymer networks derived therefrom and process for making the same | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120104316-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120104316-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010144393-A2 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144411-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308268-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308268-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | KMT2A 3598/4885ESR1 3933/4885MEN1 1865/4885 |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | TTR, CNOT9, CNOT7 | KMT2A 3298/4885ESR1 3907/4885MEN1 333/4885 |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | AQP3, AQP1, NCAPD2 | KMT2A 4073/4885ESR1 3666/4885MEN1 845/4885 |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | KMT2A 3598/4885ESR1 3933/4885MEN1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.